Meet the minds behind Radix Bioscience.
About Us
Gregory A Gould
Chief Executive Officer
& Chief Financial Officer
Dr. Stephen Morrissey,
OMD
Founder & Chief scientific officer
Staci J Eisner
Chief Operating officer
Dr. Freddie Ann Hoffman,
MD
Chief technical officer
Our Team
Dr. Stephen Morrissey, OMD
Dr. Freddie Ann Hoffman, MD
Dr. Steve R Kishter, MD, DDS
Dr. Steve R Kishter, MD, DDS
Chief Medical officer
Chief Medical officer
Gregory A Gould
Gregory A. Gould is the CEO, CFO and a Board Member of our company. With over 25 years of experience in the life sciences industry, Mr. Gould has held leadership roles in both publicly traded and privately held companies, including SeraCare Life Sciences, Atrix Laboratories, NewAge, Charlotte’s Web, Evolve Biologics, Colorado MEDtech, and Nanos Health. He has a proven track record of creating shareholder value through strategic management of mergers and acquisitions, restructurings, and financing activities, having led organizations through over $500 million in equity and debt financings, more than ten acquisitions, and the successful uplisting of three companies to NASDAQ. Mr. Gould is also recognized for his expertise in scaling businesses, achieving significant revenue growth, and building high-performing teams. He holds a Bachelor of Science in Business Administration with a focus on Finance and Accounting from the University of Colorado at Boulder and began his career at Arthur Andersen as a CPA.
Chief Executive Officer
& Chief Financial Officer
Chief Executive Officer & Chief Financial Officer
Dr. Stephen Morrissey, OMD
Dr. Stephen Morrissey, OMD
Founder &
Chief scientific officer
Dr. Stephen Morrissey is the Chief Scientific Officer and a Board Member of our company. With over 30 years of clinical experience, Dr. Morrissey specializes in herbal medicine, homeopathy, electrodiagnostic systems, and nutrition. He is a serial entrepreneur who has founded several companies, including the Five Element Herb Company, Plantiva, and Cortex Scientific. Through two joint venture companies he established in China, he has been instrumental in implementing improved standardization, quality, and safety of botanical medicines. Dr. Morrissey has been a leader in the production of botanical extracts, overseeing the sourcing and manufacture of over 200 tons of plant extracts, and has collaborated with universities to develop more than 40 health products. He also has extensive experience in conducting clinical research, having organized multiple randomized, controlled studies to validate his innovative product development approaches. Dr. Morrissey earned his Bachelor of Science in Business from the University of Denver and a Doctorate in Oriental Medicine from the California Acupuncture College.
Founder & Chief scientific officer
Staci J Eisner
Staci J Eisner
Chief Operating officer
Ms. Staci J. Eisner serves as the Chief Operating Officer of our company. She has worked as Director of Quality Assurance and Regulatory Affairs at US, Japanese, and Swiss dose form and extract manufacturers. Ms. Eisner has also been extensively involved with the Institute for Nutraceutical Advancement's Methods Validation Program, the Board of Trustees of the American Herbal Products Association (AHPA), a Board member of American Herbal Pharmacopeia, and the NSF/ANSI Joint Task Force on Dietary Supplements. She has served as managing editor of three technical documents for AHPA, focusing on industry-wide issues of quality assurance related to manufacturing, marker compounds, and standardization of botanicals. Ms. Eisner graduated with honors in both chemistry and biochemistry of natural products at Cornell University.
Dr. Freddie Ann Hoffman, MD
Dr. Freddie Ann Hoffman, MD
Chief technical officer
Dr. Freddie Ann Hoffman serves as the Chief Technical Medical Officer of our company. She is also the CEO of HeteroGeneity, LLC, a scientific and regulatory consulting firm she founded in 2003. Dr. Hoffman has an extensive background in both the public and private sectors. In including her role as Chief of the Cytokines, Growth Factors, and Oncologic Products Branch at the FDA Center for Biologics Evaluation and Research (CBER), she led a team that During her time at the FDA, she played a crucial role in the licensing of 15 biologic drugs. and She also served as in the Office of the FDA Commissioner, as the Deputy Director of the Medicine Branch, where she chaired the Agency’s Working Group on Botanical drugs, producing the Agency’s guidance on botanical drug development. Dr. Hoffman received a Bachelor of Science in Chemistry at UCLA, a Doctorate of Medicine and residency at US Davis, and completed a fellowship in pediatric hematology-oncology at the National Cancer Institute, where she conducted significant clinical and laboratory research. Following retirement from the US Public Health Service as a Captain, she served as the senior director for New Technology and Product Development at Pfizer-Warner Lambert Consumer Health Care. Her company, HeteroGeneity assisted sponsors in achieving the first two FDA New Drug Approvals for prescription botanical drugs in the United States.
Dr. Steve R Kishter, MD, DDS
Dr. Steve R Kishter, MD, DDS
Chief medical officer
Dr. Steven Kishter is our Chief Medical Officer. He is also CEO of The Avenue 16 Group LLC, a business development consultancy with a focus on naturally complex drugs. He holds an undergraduate degree in Neuroscience from McGill University and began a research career in the NCI Laboratory of Tumor Biology, led by Robert A Gallo, MD and then later in the NCI Pediatric Oncology Branch. His clinical training includes a doctorate of dental surgery from the U of Maryland and medical degree from Albany School of Medicine. During a fellowship in the NCI Surgical Oncology Branch, he worked both clinically and in the lab. His broad clinical and drug development experience includes the design, implementation, and analyses of clinical study protocols for drugs and biologics under IND, as well as the surgical procedures and care of patients with cancer, AIDs, and other conditions treated at the National Institutes of Health Clinical Center. Returning to the U of Maryland, Dr. Kishter trained and received board certification in oral-maxillofacial surgery. Moving to the private sector, he became the Medical Director for the Advil® franchise at Wyeth Consumer Healthcare, where he also served on the company’s New Technology Search Team before returning to the DC area to practice oral-max surgery, which he continues to do part-time, as he remains involved in new product development as a Medical-Clinical expert.
Introducing CG1.4
Discover the future of inflammation treatment with CG1.4, our innovative polymolecular drug candidate. Designed to address the limitations of traditional biologics, CG1.4 offers a promising solution for patients seeking relief from inflammatory and autoimmune diseases. Learn more about how CG1.4 could transform the lives of patients.
The Future of Inflammatory Disease Treatment
Learn more
Partners in Innovation
Seize the opportunity to invest in a company at the forefront of botanical drug development. Join us on our mission to revolutionize healthcare.
Invest in a brighter future
Join us
